1. Home
  2. UMC vs CINGW Comparison

UMC vs CINGW Comparison

Compare UMC & CINGW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • UMC
  • CINGW
  • Stock Information
  • Founded
  • UMC 1980
  • CINGW N/A
  • Country
  • UMC Taiwan
  • CINGW United States
  • Employees
  • UMC N/A
  • CINGW 13
  • Industry
  • UMC Semiconductors
  • CINGW Biotechnology: Pharmaceutical Preparations
  • Sector
  • UMC Technology
  • CINGW Health Care
  • Exchange
  • UMC Nasdaq
  • CINGW Nasdaq
  • Market Cap
  • UMC N/A
  • CINGW N/A
  • IPO Year
  • UMC 2000
  • CINGW 2021
  • Fundamental
  • Price
  • UMC $6.72
  • CINGW $0.06
  • Analyst Decision
  • UMC Sell
  • CINGW
  • Analyst Count
  • UMC 4
  • CINGW 0
  • Target Price
  • UMC $7.40
  • CINGW N/A
  • AVG Volume (30 Days)
  • UMC 15.6M
  • CINGW N/A
  • Earning Date
  • UMC 04-23-2025
  • CINGW N/A
  • Dividend Yield
  • UMC 6.89%
  • CINGW N/A
  • EPS Growth
  • UMC N/A
  • CINGW N/A
  • EPS
  • UMC 0.11
  • CINGW N/A
  • Revenue
  • UMC $7,086,716,942.00
  • CINGW N/A
  • Revenue This Year
  • UMC $9.39
  • CINGW N/A
  • Revenue Next Year
  • UMC $9.53
  • CINGW N/A
  • P/E Ratio
  • UMC $11.91
  • CINGW N/A
  • Revenue Growth
  • UMC 4.39
  • CINGW N/A
  • 52 Week Low
  • UMC $5.61
  • CINGW N/A
  • 52 Week High
  • UMC $9.00
  • CINGW N/A
  • Technical
  • Relative Strength Index (RSI)
  • UMC 51.43
  • CINGW N/A
  • Support Level
  • UMC $6.52
  • CINGW N/A
  • Resistance Level
  • UMC $7.87
  • CINGW N/A
  • Average True Range (ATR)
  • UMC 0.23
  • CINGW 0.00
  • MACD
  • UMC -0.00
  • CINGW 0.00
  • Stochastic Oscillator
  • UMC 14.81
  • CINGW 0.00

About CINGW Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Share on Social Networks: